Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Neuroendocrine Tumors × Somatostatin × Clear all

Phase

Status

Recruiting 3 Unknown 1 Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1 Gastric Cancer After D2 Lymph Node Dissection 1 Gallbladder Neoplasms 1 Carcinoma, Hepatocellular 1 Carcinoid Tumor 1

Interventions

Everolimus 14 Octreotide 7 lutetium Lu 177 dotatate 6 pasireotide 5 lanreotide 5 Temozolomide 5 Positron Emission Tomography Computed Tomography 5 surufatinib 4 gallium Ga 68 dotatate 4 Sunitinib 4 Data Collection 4 3-Iodobenzylguanidine 4 Etoposide 3 Carboplatin 3 Capecitabine 3 90Y-octreotide, DOTA-Tyr(3)- 3 pentetreotide 2 pembrolizumab 2 pazopanib 2 fosbretabulin 2 fluorodopa F 18 2 avelumab 2 arginyllysine 2 Sorafenib 2 Single Photon Emission Computed Tomography Computed Tomography 2 Positron-Emission Tomography 2 Pemetrexed 2 PM 01183 2 Magnetic Resonance Spectroscopy 2 Irinotecan 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04129255 2020-09-10

CSMS99

National Cancer Institute, Naples

Phase 2 Completed

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡